TrialPath
Recruiting

A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

NCT03183661 · Anterogen Co., Ltd.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101)
About this study
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-CD injection in phase 1 clinical trial (ALLO-ASC-CD-101) for 36 months. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease, such as crohn's disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease.
Eligibility criteria
Inclusion Criteria: 1. Subjects who are injected with ALLO-ASC-CD in phase 1 clinical trial of ALLO-ASC-CD-101. 2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements. Exclusion Criteria: 1\. Subjects who are considered not suitable for the study by the principal investigator.
Study design
Enrollment target: 9 participants
Age groups: adult, older_adult
Timeline
Starts: 2016-11-16
Estimated completion: 2026-12-31
Last updated: 2023-08-25
Interventions
Biological: ALLO-ASC-CD
Primary outcomes
  • • Number of Participants with Adverse Events as a Measure of Safety and Tolerability (up to 36 months)
Sponsor
Anterogen Co., Ltd. · industry
Contacts & investigators
ContactJae Hee Cheon, Ph D · contact · GENIUSHEE@yuhs.ac
InvestigatorJae Hee Cheon, Ph D · principal_investigator, Yonsei University
InvestigatorJoo Sung Kim, Ph D · principal_investigator, Seoul National University Hospital
InvestigatorYoung Ho Kim, Ph D · principal_investigator, Samsung Medical Center
All locations (2)
Seoul National University HospitalRecruiting
Seoul, South Korea
Severance HospitalCompleted
Seoul, South Korea
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial · TrialPath